Takeda Global Headquarters Grand Opening
Takeda Pharmaceutical Company Limited, (“Takeda”) (TOKYO:4502) today held the grand opening of Takeda Global Headquarters. The building, completed in March 2018, will serve as Takeda's head office for its operations worldwide.
At the grand opening, Creative Director Kashiwa Sato (SAMURAI, Inc.), Takeda's President and CEO Christophe Weber, and Takeda’s Head of Corporate Strategy and the CEO Office, Yasuhiro Fukutomi, who managed the project, took to the stage to introduce the objectives and significance of the project as the company accelerates its transformation.
“Takeda Global Headquarters symbolizes the passing on to the next generation of Takeda's unwavering identity and values as a company, with its roots in Japan, yet reaching patients worldwide," said Takeda President and CEO Weber. "Moreover, it will provide a base for our diverse workforce of around 30,000 employees across the globe where they can connect, collaborate, learn and share, in an environment designed to offer comfort and inspiration. From here in Nihonbashi, Tokyo, we will pursue our mission of contributing to better health and a brighter future for people worldwide, while nurturing our relationship with the local community.”
Kashiwa Sato said “I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s values, and its core commitment to always put patients first. In this process, I chose 'life force' as the central concept, and the eight characters for 'life', 'water', 'light', 'earth', 'trees', 'people', 'connections', and 'future' as motifs, representing this concept. Just as these basic natural elements form the wellspring that nurtures life, the bonds between people are the driving-force that enable them to tackle the biggest of challenges, and contribute to a brighter future for all. It is my hope that this building will be an inspiration to all who work here as well as to the visitors, and it will lead them to naturally want to share their thoughts on Takeda’s future.”
With Takeda Global Headquarters as a base, and a symbol of our values, we will further accelerate our transformation into becoming a global, values-based R&D-driven biopharmaceutical leader.
About Takeda Global Headquarters
Please visit the URL below for more information on Takeda Global
As the embodiment of a global brand with roots in Japan, I wanted the design of Takeda’s new headquarters to express the essence of Takeda’s DNA. These fundamental elements contribute to Takeda being the world-renowned pharmaceutical company, as well as underpinning the promise of a brighter future for all. They could also be interpreted as people’s “life force”, and it was this that I selected as the overall concept for the interior design. The concept of “life force” can also be seen to represent the fundamental point of origin of the company, and indeed, refined to reveal a vision of its future state. In this way, it can hold an important message for Takeda, and one that should be embraced and passed on to future generations. I approached the flow of movement, from the building entrance, past the reception and then on to the areas where people work, as a story of nurturing life. I chose to depict phases in this story - beginning with the source of life, followed by growth, and finally to the formation of strong connections - by associating symbolic kanji characters with each space. The characters were tuned into modern designs that convey the spirit of ”Wa” (a sense of Japanese-style harmony) which is inherent in Takeda, and applied as artwork on the walls. It is my hope that this building will be an inspiration to all who work here, and will lead them to naturally want to share their thoughts on Takeda’s future with other people that they meet on a daily basis.
Kashiwa Sato, Creative Director
Photos are available upon request.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO:
4502) is a global, research and development-driven pharmaceutical
company committed to bringing better health and a brighter future to
patients by translating science into life-changing medicines. Takeda
focuses its R&D efforts on oncology, gastroenterology and neuroscience
therapeutic areas plus vaccines. Takeda conducts R&D both internally and
with partners to stay at the leading edge of innovation. Innovative
products, especially in oncology and gastroenterology, as well as
Takeda’s presence in emerging markets, are currently fueling the growth
of Takeda. Approximately 30,000 Takeda employees are committed to
improving quality of life for patients, working with Takeda’s partners
in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0) 3-3278-2095
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Abu Dhabi to Host Interfaith Alliance For Safer Communities: Child Dignity in the Digital World Forum on 19 November17.11.2018 13:40 | Pressemelding
Held under the patronage of His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, the UAE will host the first edition of the Interfaith Alliance For Safer Communities Forum on November 19-20 in recognition of the country’s leading role in promoting tolerance and interfaith dialogue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181117005008/en/ His Highness Sheikh Mohammed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces (Photo: AETOSWire) The forum will host 450 guests including religious leaders, NGOs and heads of industry to discuss ongoing social challenges and develop comprehensive solutions for protecting youth from cybercrime. The Interfaith Alliance For Safer Communities Forum is an expansion of the Child Dignity in the Digital World Congress which was held in October 2017 in the Vatican, an
Philip Morris International and Dorna Switch Gears in Quest for a World without Tobacco Smoke17.11.2018 11:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE:PM) and Dorna Sports S.L., the commercial rights holder for the world FIM MotoGP Championships, have extended their partnership until the end of 2021. The two organizations have collaborated successfully for 26 years. As of 2019, the partnership will focus on advancing the cause of a smoke-free world. More than 1 billion people smoke today and, according to the World Health Organization, will continue to smoke in the near future. PMI has committed to transform its business and encourage all men and women who would otherwise continue smoking to replace cigarettes with better alternatives as soon as possible. With around 350 million MotoGP fans worldwide, MotoGP can play a significant role in positively impacting the lives of people who smoke and those around them. “The best choice for consumers concerned about the health risks of smoking is to quit tobacco and nicotine altogether. Today, however, technology, science and innovation provide a r
Schlumberger Announces Fourth-Quarter and Full-Year 2018 Results Conference Call16.11.2018 18:00 | Pressemelding
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 18, 2019 to discuss the results for the fourth quarter and full year ending December 31, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 18, 2019, and can be accessed by dialing +1 (800)
Visa Strengthens Commitment to Growing Digital Payments in India16.11.2018 14:33 | Pressemelding
Visa (NYSE: V) today announced a minority investment in BillDesk, a leading platform for online payments and bill payments in India. Visa’s investment and collaboration will help BillDesk develop new product lines for its payments and loyalty businesses and also expand its footprint into other geographies. The investment will be subject to necessary statutory approvals and is expected to have no direct bearing on Visa’s existing Indian business. “As a leading payments player in India, BillDesk has been a long time business partner to Visa. Having worked with BillDesk’s founders over the years, the Visa leadership has been consistently impressed with their vision, market knowledge and execution capabilities, as well as alignment on values. This investment further reinforces our long-term commitment to India’s digital payments growth story,” said Asia Pacific regional president, Chris Clark. “We are truly excited by this investment from the world's largest global payment network, Visa. W
Guidewire Enhances PartnerConnect Consulting Program with Addition of Product and Regional Specializations16.11.2018 13:55 | Pressemelding
Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform Property and Casualty (P&C) insurers rely upon, today announced the addition of specializations to its PartnerConnect Consulting program. Specializations have been added to aid insurance companies in selecting the best partner to lead or staff their Guidewire projects. Guidewire unveiled new specializations, including two which have been successfully piloted earlier this year. “Our customers will now have more clarity and information as to which partners have the proven capabilities in their chosen product and region,” said Lisa Walsh, vice president, Alliances, Guidewire Software. “Adding these specializations will also allow us to have more insight into a partner’s performance and competencies.” To earn a specialization, partners need to demonstrate skills, knowledge, and competency in a specific Guidewire product or solution by certifying staff at multiple levels (specialist and professional) through Guidewire’
Janssen receives positive CHMP opinion for ERLEADA™ (apalutamide) for patients with non-metastatic castration-resistant prostate cancer who are at high risk of developing metastatic disease16.11.2018 13:15 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for apalutamide, a next generation oral androgen receptor inhibitor for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.2 The CHMP’s positive opinion will now be reviewed by the European Commission (EC), which has the authority to grant approval for the use of apalutamide. The CHMP’s positive opinion is based on data from the pivotal SPARTAN Phase 3 clinical study which assessed the safety and efficacy of apalutamide versus placebo in patients with nmCRPC who have a rapidly rising prostate specific antigen (PSA) level despite receiving continuous androgen deprivation therapy (ADT). The SPARTAN clinical study showed that apalutamide, when added to ADT, significantly reduced the risk